Carasent AB (CARA.ST) Stock Analysis & Winston Score
Carasent is a Swedish software company that builds digital tools for doctors and healthcare clinics. Its main product is Webdoc, an electronic health record (EHR) system used by private healthcare providers across Scandinavia. The company helps clinics manage patient records, appointments, and clinical workflows in one place. Carasent makes money by charging healthcare providers recurring subscription fees for its software, which gives it a relatively predictable revenue stream. It operates primarily in Sweden, Norway, and the broader Nordic region, and its high gross margin of roughly 84% reflects the low cost of delivering software at scale. The company's main competitive advantage is the switching cost built into EHR systems — once a clinic's data and workflows are embedded in a platform, changing to a competitor is slow and disruptive. The key risk is that operating margins remain very thin, meaning the company must grow revenue significantly to prove its business model can generate meaningful profits.
Winston Score: 47/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Mixed (13/30)
- Growth: Mixed (8/20)
- Cash Flow: Strong (8/10)
- Stability: Good (5/10)
- Valuation: Good (5/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $24.20
Market Cap: $1.6B
Sector: Technology
Industry: Software - Application
Exchange: Stockholm Stock Exchange

